.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Advancements in the Management of R/R AML: ASH 2024

Panelists discuss how recent advancements in targeted therapies, particularly the FDA-approved menin inhibitor revumenib, are reshaping the treatment landscape for relapsed/refractory acute monocytic leukemia (R/R AML), offering new options for high-risk patients while emphasizing the importance of genetic testing and minimal residual disease monitoring in guiding therapy.

EP. 1: Treatment Strategies for Relapsed/Refractory AML Patients

December 20th 2024

Panelists discuss how the latest NCCN guidelines for relapsed/refractory acute monocytic leukemia (R/R AML) outline targeted therapy options outside clinical trials, and explore treatment approaches based on patient fitness, actionable biomarkers, and prior therapies, highlighting the impact of first remission duration and genetic abnormalities on treatment sequencing.